Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
03 avr. 2023 07h00 HE
|
Attralus, Inc
AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need
29 mars 2023 08h00 HE
|
Galimedix Therapeutics, Inc.
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open Innovation into Galimedix supports further...
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
23 mars 2023 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, “Vaccinex”), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
09 mars 2023 08h00 HE
|
Vaccinex, Inc.
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study...
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury
23 févr. 2023 09h20 HE
|
ZyVersa Therapeutics
Data published in Translational Research indicate that pyroptotic release of cytokines and ASC Specks from traumatic brain injury (TBI) induces a heightened inflammasome response in Alzheimer’s...
Global Alzheimer’s Platform Foundation (GAP) President Blasts CMS’ “Unprecedented and Pernicious” Discrimination Against People with Alzheimer’s Disease
23 févr. 2023 08h51 HE
|
Global Alzheimer's Platform Foundation
Washington, D.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: “Once again, the Centers for Medicare and Medicaid Services (CMS) has...
Clinical Trial Volunteers Honored with National Citizen Scientist Awards for Participating in Research
23 févr. 2023 07h00 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the recipients of the 2022 National Citizen Scientist Awards®. GAP’s...
Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
21 févr. 2023 05h00 HE
|
Amydis, Inc.
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today...
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
09 janv. 2023 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Global Alzheimer’s Platform Foundation Statement on FDA Accelerated Approval of Lecanemab
06 janv. 2023 14h25 HE
|
Global Alzheimer's Platform Foundation
Washington, D.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- "We applaud the Food and Drug Administration (FDA)’s decision to grant accelerated approval to lecanemab, a treatment that offers millions of...